Jansen, P., Galetzka, W., Lodde, G. C., Standl, F., Zaremba, A., Herbst, R., . . . Griewank, K. (2024). Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas. European journal of cancer, 208, . https://doi.org/10.1016/j.ejca.2024.114208
Chicago-Zitierstil (17. Ausg.)Jansen, Philipp, et al. "Shortened Progression Free and Overall Survival to Immune-checkpoint Inhibitors in BRAF-, RAS- and NF1- (“Triple”) Wild Type Melanomas." European Journal of Cancer 208 (2024). https://doi.org/10.1016/j.ejca.2024.114208.
MLA-Zitierstil (9. Ausg.)Jansen, Philipp, et al. "Shortened Progression Free and Overall Survival to Immune-checkpoint Inhibitors in BRAF-, RAS- and NF1- (“Triple”) Wild Type Melanomas." European Journal of Cancer, vol. 208, 2024, https://doi.org/10.1016/j.ejca.2024.114208.